Limaprost-d3

• UNSPSC Description:

  Limaprost-d3 (17α,20-dimethyl-δ2-PGE1-d3) is the deuterium labeled Limaprost. Limaprost (OP1206) is a PGE1 analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research[1][2].

• Target Antigen:

  Isotope-Labeled Compounds; PGE synthase

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Immunology/Inflammation;Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  C(CCCC=CC(O)=O)[C@@H]1[C@@H](C=C[C@H](C[C@H](CCCC)[C@]([2H])([2H])[2H])O)[C@H](O)CC1=O

• Molecular Weight:

  383.54

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Tsuboi T, et al. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther. 1980 Sep;247(1):89-102.|[3]Swainston Harrison T, et al. Limaprost. Drugs. 2007;67(1):109-18; discussion 119-20.|[4]Murata K, et al. PGE1 Attenuates IL-1β-induced NGF Expression in Human Intervertebral Disc Cells. Spine (Phila Pa 1976). 2016 Jun;41(12):E710-6.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1263190-37-9